Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;38(5):523-7.
doi: 10.1016/j.canep.2014.06.009. Epub 2014 Aug 10.

Statin use and risk of hepatocellular carcinoma in a U.S. population

Katherine A McGlynn  1 , George W Divine  2 , Vikrant V Sahasrabuddhe  3 , Lawrence S Engel  4 , Ashley VanSlooten  2 , Karen Wells  2 , Marianne Ulcickas Yood  5 , Sharon Hensley Alford  2
Affiliations

Statin use and risk of hepatocellular carcinoma in a U.S. population

Katherine A McGlynn et al. Cancer Epidemiol. 2014 Oct.

Abstract

Purpose: Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are medications widely prescribed to reduce cholesterol levels. Observational studies in high-risk populations, mostly in Asia, have suggested that statins are associated with a reduced risk of hepatocellular carcinoma (HCC). The current study sought to evaluate the association of statin use and HCC in a U.S.-based, low-risk, general population.

Methods: A nested case-control study was conducted among members of the Health Alliance Plan HMO of the Henry Ford Health System enrolled between 1999 and 2010. Electronic pharmacy records of statin use were compared among tumor registry-confirmed cases of HCC (n=94) and controls (n=468) matched on age, sex, diagnosis date, and length of HMO enrolment.

Results: In multivariate analyses, ever-use of statins was significantly inversely associated with development of HCC (Odds ratio (OR): 0.32, 95%CI: 0.15-0.67). No clear dose-response relationship was evident as statin use for <2 years (OR=0.32, 95%CI=0.13-0.83) and >2 years (OR=0.31, 95CI%=0.12-9.81) resulted in very similar ORs.

Conclusions: The use of statins among populations in low-risk HCC areas may be associated with decreased risk of HCC.

Keywords: Epidemiology; Liver cancer; Statins.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None to declare

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomatarm I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer; 2013.
    1. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–243. vii–x. - PMC - PubMed
    1. Chen JG, Kensler TW. Changing rates for liver and lung cancers in Qidong, China. Chem Res Toxicol. 2014;27:3–6. - PMC - PubMed
    1. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314–1321. - PMC - PubMed
    1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. - PMC - PubMed

Publication types

Substances

LinkOut - more resources